SG11201506635TA - Caix stratification based cancer treatment - Google Patents
Caix stratification based cancer treatmentInfo
- Publication number
- SG11201506635TA SG11201506635TA SG11201506635TA SG11201506635TA SG11201506635TA SG 11201506635T A SG11201506635T A SG 11201506635TA SG 11201506635T A SG11201506635T A SG 11201506635TA SG 11201506635T A SG11201506635T A SG 11201506635TA SG 11201506635T A SG11201506635T A SG 11201506635TA
- Authority
- SG
- Singapore
- Prior art keywords
- caix
- cancer treatment
- based cancer
- stratification based
- stratification
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000013517 stratification Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361768084P | 2013-02-22 | 2013-02-22 | |
| US201361829349P | 2013-05-31 | 2013-05-31 | |
| PCT/EP2014/053420 WO2014128258A1 (en) | 2013-02-22 | 2014-02-21 | Caix stratification based cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201506635TA true SG11201506635TA (en) | 2015-09-29 |
Family
ID=50179596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201506635TA SG11201506635TA (en) | 2013-02-22 | 2014-02-21 | Caix stratification based cancer treatment |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10620208B2 (ko) |
| EP (1) | EP2958589B1 (ko) |
| JP (1) | JP2016511766A (ko) |
| KR (1) | KR102172403B1 (ko) |
| CN (2) | CN110208535A (ko) |
| AU (1) | AU2014220705C1 (ko) |
| BR (1) | BR112015020061A8 (ko) |
| CA (1) | CA2901531C (ko) |
| ES (1) | ES2703572T3 (ko) |
| HK (1) | HK1215195A1 (ko) |
| IL (1) | IL240499B (ko) |
| MX (1) | MX363845B (ko) |
| NZ (1) | NZ712023A (ko) |
| RU (1) | RU2663694C2 (ko) |
| SG (1) | SG11201506635TA (ko) |
| WO (1) | WO2014128258A1 (ko) |
| ZA (1) | ZA201505937B (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110208535A (zh) | 2013-02-22 | 2019-09-06 | 威丽克斯股份公司 | 基于caix分级的癌症治疗 |
| EP4031667B1 (en) | 2019-09-16 | 2023-11-01 | Bracco Imaging SPA | Ca-ix aptamers and diagnostic and therapeutic uses thereof |
| CN110862457B (zh) * | 2019-12-05 | 2021-09-24 | 中国人民解放军陆军特色医学中心 | 能与碳酸酐酶ix特异性结合的骆驼源纳米抗体及其应用 |
| WO2024023144A1 (en) | 2022-07-28 | 2024-02-01 | Bracco Imaging Spa | Ca-ix targeting fluorescent probes |
| WO2024023138A2 (en) | 2022-07-28 | 2024-02-01 | Bracco Imaging Spa | Ca-ix targeting fluorescent probes |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0366707A1 (en) | 1987-05-06 | 1990-05-09 | OOSTERWIJK, Egbert | Monoclonal antibodies to renal cell carcinoma |
| US5981711A (en) | 1992-03-11 | 1999-11-09 | Institute Of Virology, Slovak Academy Of Sciences | MN-specific antibodies and hybridomas |
| US6093548A (en) | 1992-03-11 | 2000-07-25 | Institute Of Virology, Slovak Academy Of Sciences | Detection and quantitation of MN-specific antibodies. |
| US5989838A (en) | 1992-03-11 | 1999-11-23 | Institute Of Virology, Slovak Academy Of Sciences | Immunological methods of detecting MN proteins and MN polypeptides |
| US5387676A (en) | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
| WO1995034650A2 (en) | 1994-06-15 | 1995-12-21 | Ciba Corning Diagnostics Corp. | Mn gene and protein |
| DK1123387T3 (da) | 1998-10-23 | 2008-02-25 | Inst Virology | MN-gen og protein |
| AU2002238537B8 (en) | 2001-02-07 | 2006-08-24 | Wilex Ag | Hybridoma cell line G250 and its use for producing monoclonal antibodies |
| WO2002098897A2 (en) * | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| CA2467738A1 (en) * | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
| US7910549B2 (en) | 2001-12-13 | 2011-03-22 | Institute Of Virology Of The Slovak Academy Of Sciences | MN gene and protein |
| DE60328477D1 (de) * | 2002-04-16 | 2009-09-03 | Univ California | Verfahren zur prognose von nierenzellkarzinom und behandlungsauswahl mit carboanhydrase ix |
| DE10240118A1 (de) | 2002-08-30 | 2004-03-11 | Wilex Ag | Verfahren zur Identifizierung von Nierenzellkarzinom spezifischen Proteinen und deren Verwendung |
| KR101130181B1 (ko) * | 2003-02-27 | 2012-03-28 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 인플루엔자 바이러스 감염의 치료 및 검출에 유용한 핵산분자, 폴리펩티드, 항체 및 이를 포함하는 조성물 |
| KR20120035234A (ko) * | 2003-04-11 | 2012-04-13 | 메디뮨 엘엘씨 | 재조합 ｉｌ?９ 항체 및 그의 용도 |
| JP4905957B2 (ja) | 2003-10-16 | 2012-03-28 | インスティトゥート オブ ヴァイロロジー | Ｍｎ／ｃａ ｉｘおよび癌予後診断 |
| JP4426621B2 (ja) * | 2004-05-04 | 2010-03-03 | バイエル ヘルスケア エルエルシー | Ｍｎ／ｃａ ｉｘ／ｃａ９及び腎臓癌の予後診断 |
| CA2566950A1 (en) * | 2004-07-02 | 2006-01-12 | Wilex Ag | Improved adjuvant therapy of g250-expressing tumors |
| US7820159B2 (en) * | 2006-10-31 | 2010-10-26 | Instiute of Virology of the Slovak Academy of Sciences | MN/CA IX and EGFR pathway inhibition |
| US8492520B2 (en) * | 2007-11-02 | 2013-07-23 | Wilex Ag | Binding epitopes for G250 antibody |
| JP2011509304A (ja) * | 2008-01-09 | 2011-03-24 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 炭酸脱水酵素ｉｘの阻害剤 |
| US20120207672A1 (en) * | 2009-09-15 | 2012-08-16 | Wilex Ag | Selective detection of bone metastases in renal clear cell carcinoma |
| WO2011139375A1 (en) * | 2010-05-06 | 2011-11-10 | Ludwig Institute For Cancer Research Ltd | Antibodies directed against carbonic anhydrase ix and methods and uses thereof |
| CN110208535A (zh) | 2013-02-22 | 2019-09-06 | 威丽克斯股份公司 | 基于caix分级的癌症治疗 |
-
2014
- 2014-02-21 CN CN201910448310.2A patent/CN110208535A/zh active Pending
- 2014-02-21 KR KR1020157025649A patent/KR102172403B1/ko active IP Right Grant
- 2014-02-21 AU AU2014220705A patent/AU2014220705C1/en active Active
- 2014-02-21 US US14/769,541 patent/US10620208B2/en active Active
- 2014-02-21 MX MX2015010740A patent/MX363845B/es active IP Right Grant
- 2014-02-21 CA CA2901531A patent/CA2901531C/en active Active
- 2014-02-21 NZ NZ71202314A patent/NZ712023A/en unknown
- 2014-02-21 RU RU2015140139A patent/RU2663694C2/ru active
- 2014-02-21 JP JP2015558463A patent/JP2016511766A/ja active Pending
- 2014-02-21 SG SG11201506635TA patent/SG11201506635TA/en unknown
- 2014-02-21 BR BR112015020061A patent/BR112015020061A8/pt not_active Application Discontinuation
- 2014-02-21 WO PCT/EP2014/053420 patent/WO2014128258A1/en active Application Filing
- 2014-02-21 EP EP14706543.7A patent/EP2958589B1/en active Active
- 2014-02-21 ES ES14706543T patent/ES2703572T3/es active Active
- 2014-02-21 CN CN201480018654.5A patent/CN105377295A/zh active Pending
-
2015
- 2015-08-10 IL IL240499A patent/IL240499B/en active IP Right Grant
- 2015-08-18 ZA ZA201505937A patent/ZA201505937B/en unknown
-
2016
- 2016-03-22 HK HK16103308.3A patent/HK1215195A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX363845B (es) | 2019-04-05 |
| KR102172403B1 (ko) | 2020-11-02 |
| IL240499A0 (en) | 2015-09-24 |
| AU2014220705A1 (en) | 2015-09-10 |
| CA2901531A1 (en) | 2014-08-28 |
| BR112015020061A8 (pt) | 2018-01-23 |
| EP2958589A1 (en) | 2015-12-30 |
| CA2901531C (en) | 2022-03-29 |
| US10620208B2 (en) | 2020-04-14 |
| AU2014220705B2 (en) | 2018-05-17 |
| KR20150119406A (ko) | 2015-10-23 |
| IL240499B (en) | 2020-02-27 |
| CN105377295A (zh) | 2016-03-02 |
| ZA201505937B (en) | 2019-10-30 |
| US20160002350A1 (en) | 2016-01-07 |
| NZ712023A (en) | 2019-10-25 |
| MX2015010740A (es) | 2016-04-11 |
| HK1215195A1 (zh) | 2016-08-19 |
| WO2014128258A1 (en) | 2014-08-28 |
| BR112015020061A2 (pt) | 2017-07-18 |
| AU2014220705C1 (en) | 2018-10-18 |
| ES2703572T3 (es) | 2019-03-11 |
| EP2958589B1 (en) | 2018-11-21 |
| CN110208535A (zh) | 2019-09-06 |
| RU2663694C2 (ru) | 2018-08-08 |
| JP2016511766A (ja) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267242B (en) | Cancer treatment | |
| HK1213444A1 (zh) | 癌症的治療 | |
| GB201322725D0 (en) | Cancer therapy | |
| HK1220900A1 (zh) | 癌症的治療 | |
| SG11201507847UA (en) | Cancer therapy | |
| GB201308440D0 (en) | Therapeutic | |
| HK1215195A1 (zh) | 基於 分層的癌症治療 | |
| GB201310755D0 (en) | Therapy | |
| HK1210023A1 (en) | Cancer treatment | |
| EP2961412A4 (en) | CANCER THERAPY | |
| HUE049301T2 (hu) | Kurkofenol-vegyület rák kezelésére | |
| GB201318668D0 (en) | Sonosensitive therapeutic | |
| GB201307269D0 (en) | Combination Therapy | |
| GB201308039D0 (en) | Photodynamic therapy | |
| GB201518731D0 (en) | Tumour Therapy | |
| GB201222563D0 (en) | Cancer treatment | |
| GB201317213D0 (en) | Cancer Therapy | |
| GB201300546D0 (en) | Cancer Treatment | |
| GB201321531D0 (en) | Treatment for cancers | |
| GB201306394D0 (en) | Cancer biomarker | |
| GB201308365D0 (en) | Tumour therapy | |
| GB201309967D0 (en) | Therapeutic combinations | |
| GB201322764D0 (en) | Treating places | |
| GB201305073D0 (en) | Therapeutic means | |
| GB201311131D0 (en) | Greensleeves II |